CURRICULUM VITAE

Ronca Roberto, PhD
Associate Professor in General pathology
University of Brescia

Personal data

born on July 30, 1975 in Desenzano del Garda (Brescia), Italy. Italian.
Work address: Section of Experimental Oncology and Immunology, Dept. of Molecular and Translational medicine, University of Brescia, Viale Europa 11 – 25123 Brescia.
Phone number: +39 030 3717735; e-mail: roberto.ronca@unibs.it
Tax code: RNCRRT75L30D284V

Education

2003: PhD in Cellular and molecular biotechnologies applied to the biomedical field. School of Medicine, University of Brescia.
1999: Master degree in Biology, University of Padua.

Research experience

04/2019- to date: Associate Professor in General Pathology, University of Brescia.
12/2010-03/2019: Researcher/Assistant Professor in General Pathology, University of Brescia. Targeting FGF/FGFR system for anti-angiogenic/anti-tumor therapies
2008-2010 post-doc fellow in General Pathology Dept. of Biomedical Sciences and Biotechnology.
2005: three years FIRC fellow; generation of anti-FGFR1 scFv antibodies for anti-angiogenic/anti-tumor therapy.
2004-2005: post-doc fellow in General Pathology Dept. of Biomedical Sciences and Biotechnology, University of Brescia;
04/2003-11/2003: attended the Dept. of Chemistry and applied Biosciences, Swiss Federal Institute of Technology (ETH) of Zurich to develop monoclonal antibodies for tumor immunotherapy;
10/2000-12/2003: PhD at Dept. of Biomedical Sciences and Biotechnology, University of Brescia to study the role of FGF/FGFR1 in tumor angiogenesis and in cardiovascular development;
09/1999-09/2000 post-graduate training Molecular Medicine Dept (R&D) of GlaxoSmithKline (Verona). Focus: generation of transgenic mouse models.
1998-1999: Surgical and Oncological Sciences Dept. University of Padua. Tumor immunology and antitumor DNA vaccination.

Technical skills and competences

Field of research: various aspects of general pathology and experimental oncology including tumor immunotherapy, DNA vaccines for tumor therapy; FGF/FGFR1 system in tumor angiogenesis and in cardiovascular development; monoclonal antibodies as anti-neoplastic agents.
Skills: Molecular biology and cellular biology, in vitro and in vivo angiogeniesis and tumorigenesis assays, production and characterization of recombinant protein, animal handling in general (injection, colony breeding…), phage display.

Narrative Biosketch

Dr. Roberto Ronca, University Researcher and Assistant Professor in General Pathology at the Department of Molecular and Translational Medicine at the University of Brescia has a long-lasting experience in experimental oncology, including the study in vitro and in vivo of tumor growth and tumor angiogenesis.
I started my research activity in tumor immunotherapy at the Surgical and Oncological Sciences Dept. at the University of Padua developing anti-tumor vaccines and studying tumor immunology and suppressor cells. From 2001, I approached tumor angiogenesis in Prof. Marco Presta's laboratory in Brescia where I studied the role of pro-angiogenic factors in vascular biology and in tumor angiogenesis, focusing on the role of FGF/FGFR system. During this period I took part to the identification of the non-redundant role of FGFR1 for cardiomyocytes differentiation. Relevant to cancer research I took part to projects aimed to identified the gene expression profile of endothelial cells after stimulation with FGF2 and also to identification of small heparin-like molecules for anti-FGF therapies. In 2003 in Zurich (Prof. Dario Neri's

laboratory) I approached phage display technology for the realization of humanized antibodies for cancer therapy and took part to the realization of therapeutic anti-tumor/anti-angiogenic antibodies fused with cytokines (i.e. IFNγ). Also, in 2003 I was awarded by the Italian Foundation for Cancer Research with a 3 years fellowship and in the frame of this FIRC fellowship I realized a human scFv antibody neutralizing the FGFR1 biological activity in vitro and in vivo. In the last years I deepened the study of tumor-stroma interactions and tumor growth to develop therapeutic approaches based both on decoy molecules and antibodies as anti-cancer and anti-angiogenetic agents. Recently I studied the capacity of the protein long pentraxin 3 (PTX3) to bind FGF2 (and other FGFs) and antagonize its biological activities in vitro and in vivo. These studies were published so far and report the anti-tumor role of PTX3 in different cancer types, and the possibility to use PTX3 to develop anti-FGF/FGFR system therapeutics.

Publications

1. Morigi R, Locatelli A, Leoni A, Rambaldi M, Bortolozzi R, Mattiuzzo E, **Ronca R**, Maccarinelli F, Hamel E, Bai R, Brancale A, Viola G. Synthesis, in vitro and in vivo biological evaluation of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones as new potent anticancer agents. Eur J Med Chem. 2019 Mar 15;166:514-530. doi: 10.1016/j.ejmech.2019.01.049
2. Codenotti S, Faggi F, **Ronca R,** Chiodelli P, Grillo E, Guescini M, Megiorni F, Marampon F, Fanzani A. Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation. Cancer Lett. 2019 Feb 13;449:135-144. doi: 10.1016/j.canlet.2019.02.013
3. Vrijens P, Noppen S, Boogaerts T, Vanstreels E, **Ronca R**, Chiodelli P, Laporte M, Vanderlinden E, Liekens S, Stevaert A, Naesens L. Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor β signalling pathway. J Gen Virol. 2019 Feb 14. doi: 10.1099/jgv.0.001235.
4. Romagnoli R, Prencipe F, Oliva P, Baraldi S, Baraldi PG, Schiaffino Ortega S, Chayah M, Kimatrai Salvador M, Lopez-Cara LC, Brancale A, Ferla S, Hamel E, **Ronca R**, Bortolozzi R, Mariotto E, Mattiuzzo E, Viola G. Design, Synthesis and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. J Med Chem. 2019 Jan 11. doi: 10.1021/acs.jmedchem.8b01391
5. Rodrigues PF, Matarazzo S, Maccarinelli F, Foglio E, Giacomini A, Silva Nunes JP, Presta M, Dias AAM, **Ronca R.** Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. Front Oncol. 2018 Nov 1;8:472. doi: 10.3389/fonc.2018.00472.
6. Mariotto E, Viola G, **Ronca R**, Persano L, Aveic S, Bhujwalla ZM, Mori N, Accordi B, Serafin V, López-Cara LC, Bortolozzi R. Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast Cancer. Cancers (Basel). 2018 Oct 22;10(10). pii: E391. doi: 10.3390/cancers10100391.
7. Presta M, Foglio E, Churruca Schuind A, **Ronca R**. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2. Front Immunol. 2018 Oct 8;9:2327. doi: 10.3389/fimmu.2018.02327
8. Roncato F, Rruga F, Porcù E, Casarin E, **Ronca R**, Maccarinelli F, Realdon N, Basso G, Alon R, Viola G, Morpurgo M Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies. Nat Commun. 2018 Oct 4;9(1):4070. doi: 10.1038/s41467-018-06602-6.
9. Ghedini GC, **Ronca R**, Presta M, Giacomini A.
   Future applications of FGF/FGFR inhibitors in cancer. Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872.
10. Bosisio D, **Ronca R*,** Salvi V, Presta M, Sozzani S.
    Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. Curr Opin Immunol. 2018 Jun 4;53:180-186. *Equal contribution
11. Busatto S, Giacomini A, Montis C, **Ronca R**, Bergese P.
    Uptake Profiles of Human Serum Exosomes by Murine and Human Tumor Cells through Combined Use of Colloidal Nanoplasmonics and Flow Cytofluorimetric Analysis. Anal Chem. 2018 Jun 15. doi: 10.1021/acs.analchem.7b04374.
12. Giacomini A, Ghedini GC, Presta M, **Ronca R.**
    Long pentraxin 3: A novel multifaceted player in cancer. BBA Rev on cancer. 2018 Jan;1869(1):53-63.
13. **Ronca R**, Van Ginderachter JA, Turtoi A.
    Paracrine interactions of cancer-associated fibroblasts, macrophages and endothelial cells: tumor allies and foes. Curr Opin Oncol. 2018 Jan; 30(1):45-53.
14. Chiodelli P, Rezzola S, Urbinati C, Federici Signori F, Monti E, **Ronca R**, Presta M, Rusnati M.

Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene. 2017 Aug 7. doi: 10.1038/onc.2017.243

15. **Ronca R**., Tamma R., Coltrini D., Ruggieri S., Presta M. and Ribatti D.
Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. Oncotarget. 2017 Aug. doi: 10.18632/oncotarget.19773.
16. **Ronca R**, Benkheil M, Mitola S, Struyf S, Liekens S.
Tumor angiogenesis revisited: Regulators and clinical implications. Med Res Rev. 2017 Jun 23. doi: 10.1002/med.21452.
17. Presta M, Chiodelli P, Giacomini A, Rusnati M, **Ronca R.**
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017 May 28.
18. Caccuri F, **Ronca R***, Laimbacher AS, Berenzi A, Steimberg N, Campilongo F, Mazzuca P, Giacomini A, Mazzoleni G, Benetti A, Caselli E, Presta M, Di Luca D, Fraefel C, Caruso A.
U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. Oncotarget. 2017 May 11. doi: 10.18632/oncotarget.17817. ***Co-First author**
19. Romagnoli R, Baraldi PG, Prencipe F, Oliva P, Baraldi S, Salvador MK, Lopez-Cara LC, Brancale A, Ferla S, Hamel E, **Ronca R**, Bortolozzi R, Mariotto E, Porcù E, Basso G, Viola G.
Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents. Sci Rep. 2017 Apr 13;7:46356. doi: 10.1038/srep46356.
20. Rezzola S, Corsini M, Chiodelli P, Cancarini A, Nawaz IM, Coltrini D, Mitola S, **Ronca R**, Belleri M, Lista L, Rusciano D, De Rosa M, Pavone V, Semeraro F, Presta M.
Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. Diabetologia. 2017 Apr;60(4):719-728.
21. Porcù E, Persano L, **Ronca R**, Mitola S, Bortolozzi R, Romagnoli R, Oliva P, Basso G, Viola G.
The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation. Sci Rep. 2016 Jun 13;6:27886. doi: 10.1038/srep27886.
22. Porcù E, Salvador A, Primac I, Mitola S, **Ronca R**, Ravelli C, Bortolozzi R, Vedaldi D, Romagnoli R, Basso G, Viola G.
Vascular disrupting activity of combretastatin analogues. Vascul Pharmacol. 2016 Aug;83:78-89.
23. Romagnoli R, Baraldi PG, Prencipe F, Oliva P, Baraldi S, Tabrizi MA, Lopez-Cara LC, Ferla S, Brancale A, Hamel E, **Ronca R**, Bortolozzi R, Mariotto E, Basso G, Viola G.
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole. Sci Rep. 2016 May 24;6:26602. doi: 10.1038/srep26602
24. Grillo E, Ravelli C, Corsini M, Ballmer-Hofer K, Zammataro L, Oreste P, Zoppetti G, Tobia C, **Ronca R**, Presta M, Mitola S.
Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. Oncotarget. 2016 May 11. doi: 10.18632/oncotarget.9286. [Epub ahead of print]
25. Castelli R, Giacomini A, Anselmi M, Bozza N, Vacondio F, Rivara S, Matarazzo S, Presta M, Mor M, **Ronca R**
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. J Med Chem. 2016 May 26;59(10):4651-63
26. Giacomini A, Chiodelli P, Matarazzo S, Rusnati M, Presta M, **Ronca R**.
Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. Pharmacol Res. 2016 May;107:172-85.
27. Peixoto P, Blomme A, Costanza B, **Ronca R**, Rezzola S, Palacios AP, Schoysman L, Boutry S, Goffart N, Peulen O, Maris P, Di Valentin E, Hennequière V, Bianchi E, Henry A, Meunier P, Rogister B, Muller RN, Delvenne P, Bellahcène A, Castronovo V, Turtoi A.
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. Oncogene. 2016 Aug 25;35(34):4481-94.
28. **Ronca R**, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, Matarazzo S, Rezzola S, Maiolo D, Torrella R, Moroni E, Mazzieri R, Escobar G, Mor M, Colombo G, Presta M.
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell. 2015 Aug 10;28(2):225-39.
29. **Ronca R**, Giacomini A, Rusnati M, Presta M.

The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin Ther Targets. 2015 Jun 30:1-17.

30. Giacomini A, Matarazzo S, Pagano K, Ragona L, Rezzola S, Corsini M, Di Salle E, Presta M, **Ronca R**.
A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget. 2015 May 30;6(15):13790-802.
31. Faggi F, Chiarelli N, Colombi M, Mitola S, **Ronca R**, Madaro L, Bouche M, Poliani PL, Vezzoli M, Longhena F, Monti E, Salani B, Maggi D, Keller C, Fanzani A.
Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest. 2015 Jun;95(6):585-602.
32. Romagnoli R, Baraldi PG, Salvador MK, Prencipe F, Lopez-Cara C, Schiaffino Ortega S, Brancale A, Hamel E, Castagliuolo I, Mitola S, **Ronca R**, Bortolozzi R, Porcù E, Basso G, Viola G.
Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin. J Med Chem. 2015 Apr 9;58(7):3209-22.
33. Liekens S, Noppen S, Gijsbers S, Sienaert R, **Ronca R**, Tobia C, Presta M.
The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget. 2015 Mar 10;6(7):4633-48.
34. Zizioli D, Guarienti M, Tobia C, Gariano G, Borsani G, Bresciani R, **Ronca R**, Giacopuzzi E, Preti A, Gaudenzi G, Belleri M, Di Salle E, Fabrias G, Casas J, Ribatti D, Monti E, Presta M.
Molecular cloning and knockdown of galactocerebrosidase in zebrafish: new insights into the pathogenesis of Krabbe's disease. Biochim Biophys Acta. 2014 Apr;1842(4):665-75.
35. Pisanti S, Picardi P, Ciaglia E, Margarucci L, **Ronca R**, Giacomini A, Malfitano AM, Casapullo A, Laezza C, Gazzerro P, Bifulco M.
Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation. FASEB J. 2014 Mar;28(3):1132-44.
36. **Ronca R**, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M.
Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Ther. 2013 Dec;12(12):2760-71.
37. Belleri M, **Ronca R**, Coltrini D, Nico B, Ribatti D, Poliani PL, Giacomini A, Alessi P, Marchesini S, Santos MB, Bongarzone ER, Presta M.
Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy. Brain. 2013 Sep;136(Pt 9):2859-75.
38. Porcù E, Viola G, Bortolozzi R, Persano L, Mitola S, **Ronca R**, Presta M, Romagnoli R, Baraldi PG, Basso G.
TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. Angiogenesis. 2013 Mar 2.
39. **Ronca R**, Alessi P, Coltrini D, Salle ED, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M.
Long Pentraxin-3 As An epithelial-Stromal Fibroblast Growth Factor-Targeting Inhibitor In Prostate Cancer. J Pathol. 2013 Feb 19.
40. Coltrini D, Di Salle E, **Ronca R**, Belleri M, Testini C, Presta M.
Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis. 2013 Apr;16(2):469-77.
41. **Ronca R**, Benzoni P, De Luca A, Crescini E, Dell'era P.
Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics. Int J Mol Sci. 2012;13(4):5254-77
42. Leali D, Inforzato A, **Ronca R**, Bianchi R, Belleri M, Coltrini D, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M.
Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):696-703.
43. Leali D, Alessi P, Coltrini D, **Ronca R**, Corsini M, Nardo G, Indraccolo S, Presta M.
Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther. 2011 Sep;10(9):1600-10.
44. **Ronca R**, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, Alessi P, Coltrini D, Calza S, Presta M, Dell'Era P.

Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther. 2010 Dec;9(12):3244-53.

45. D. Coltrini* **R. Ronca*,** M. Belleri, L. Zardi, S. Indraccolo, S. Valentina, R. Gavazzi, and M. Presta.
Impact of VEGF-dependent tumor microenvironment on EDB fibronectin expression by subcutaneous human tumor xenografts in nude mice Journal of Pathology, 2009 Sep 17. ***Co-first author**
46. **R. Ronca**, S. Sozzani, M. Presta, P. Alessi.
Delivering cytokines at tumour site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case Immunobiology. 2009; 214(9-10):800-10
47. **R. Ronca**, L. Gualandi, S. Calza, M. Presta and P. Dell'Era.
Fibroblast growth factor receptor-1 phosphorylation requirement for cardiomyocite differentiation in murine embryonic stem cells. Journal of Cellular and Molecular Medicine Aug;13(8A):1489-98.
48. M. Presta, G. Andrés, D. Leali, P. Dell'Era, **R. Ronca**.
Inflammatory cells and chemokines sustain FGF2-induced Angiogenesis European Cytokine Network, 2009 Jun;20(2):39-50.
49. Presta M, Dell'Era P, Mitola S, Moroni E, **Ronca R**, Rusnati M.
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Reviews 2005 Apr;16(2):159-78.
50. Ebbinghaus C, **Ronca R**, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D.
Engineering a vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. International Journal of Cancer. 2005 Aug 20;116(2):304-13.
51. P. Magnusson, **R. Ronca**, P. Dell'Era, P. Carlstedt, L. Jakobsson, J. Partanen, J. Rossant and L. Claesson- Welsh.
Expression of FGFR-1 in endothelial cells during vascular development and in teratomas. Arterioscler Thromb Vasc Biol. 2005 Mar 17
52. Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, **Ronca R**, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D.
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):71-6.
53. Dell'Era, **R. Ronca**, L. Coco, M. Metra and M. Presta.
Fibroblast growth factor receptor-1 is essential for in vitro murine cardiomyocyte development. Circulation Research 2003; Sep 5; 93(5):414-20
54. R. Giavazzi, B. Sennino, D. Coltrini, A. Garofano, M. Poli, **R. Ronca**, M.P. Molinari Tosatti and M. Presta.
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. American Journal of Pathology 2003; Jun 162(6): 1913-26.
55. M. Presta, D. Leali, H. Stabile, **R. Ronca**, M. Camozzi, L. Coco, E. Moroni, S. Liekens and M. Rusnati.
Heparin derivates as angiogenesis inhibitors. Current Pharmaceutical Design 2003 ; 9(7): 553-66
56. Dell'Era P., Coco L., **Ronca R**., Sennino B. and Presta M.
Gene expression profile in fibroblast growth factor 2- transformed endothelial cells. Oncogene 2002 Apr 4;21(15):2433-40
57. Bronte V, Apolloni E, Cabrelle A, **Ronca R**, Serafini P, Zamboni P, Restifo NP, Zanovello P.
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000 December 1; 96(12): 3838-46
58. V. Bronte, E. Apolloni, **R. Ronca**, P. Zamboni, W. W. Overwijk, D. R. Surman, N. P. Restifo, and P. Zanovello.
Genetic Vaccination with "Self" Tyrosinase-related Protein 2 Causes Melanoma Eradication but not Vitiligo. Cancer Research 60, 253-258, January 15, 2000

Brescia, March 9, 2019